☆ 4.6 Article

Anti-LGALS3BP antibody-drug conjugate treatment induces durable and potent antitumor response in a preclinical model of adenoid cystic carcinoma

ORAL ONCOLOGY (2024)

Related references

Note: Only part of the references are listed.

Article Oncology

Extracellular LGALS3BP: a potential disease marker and actionable target for antibody-drug conjugate therapy in glioblastoma

Beatrice Dufrusine et al.

Summary: This study demonstrates that vesicular galectin-3-binding protein (LGALS3BP) is a potential diagnostic biomarker and therapeutic target for glioblastoma multiforme (GBM). Immunohistochemical analysis shows high expression of LGALS3BP in GBM patient tissues, and the amount of vesicular LGALS3BP is increased compared to healthy donors. Furthermore, analysis of extracellular vesicles from mice with human GBM indicates that LGALS3BP can be used as a marker for liquid biopsy. An antibody-drug conjugate (ADC) targeting LGALS3BP, named 1959-sss/DM4, shows specific accumulation in tumor tissue and produces potent antitumor activity. Overall, this work provides evidence for the importance of LGALS3BP as a diagnostic biomarker and therapeutic target for GBM, warranting further validation in preclinical and clinical studies.

MOLECULAR ONCOLOGY (2023)

Add to Collection

Article Medicine, Research & Experimental

Visualizing Galectin-3 Binding Protein Expression with ImmunoPET

Outi Keina''nen et al.

Summary: Galectin-3 binding protein (Gal-3BP) is a glycoprotein overexpressed and secreted by several cancers, and has been identified as a marker for tumor progression and poor prognosis in various cancer types. In this study, a pair of Gal-3BP-targeting radioimmunoconjugates for Zr-89-immunoPET were developed and evaluated. The results suggest that these probes could be clinically useful for imaging Gal-3BP-expressing malignancies and identifying patients likely to respond to Gal-3BP-targeted therapeutics.

MOLECULAR PHARMACEUTICS (2023)

Add to Collection

Review Oncology

Drug-based therapy for advanced adenoid cystic carcinoma: Current landscape and challenges based on an overview of registered clinical trials

Vivian Petersen Wagner et al.

Summary: Adenoid cystic carcinoma (ACC) has a significant patient population that lacks effective systemic therapy. We reviewed ACC clinical trials on ClinicalTrials.gov and found that most trials were one-arm phase II trials enrolling advanced, recurrent/metastatic, incurable ACC cases. Small-molecule inhibitors, such as Apatinib, Axitinib, and Lenvatinib, showed promising results. However, more efforts are urgently needed in this field to improve the overall median time to progression.

CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY (2023)

Add to Collection

Article Oncology

Systemic and Targeted Therapies in Adenoid Cystic Carcinoma

Alec J. Kacew et al.

CURRENT TREATMENT OPTIONS IN ONCOLOGY (2023)

Add to Collection

Article Dentistry, Oral Surgery & Medicine

LGALS3BP is a potential target of antibody-drug conjugates in oral squamous cell carcinoma

Ilaria Cela et al.

Summary: The present study suggests that LGALS3BP is highly expressed in oral squamous cell carcinoma (OSCC) and may serve as a potential diagnostic biomarker and therapeutic target for ADC-based therapy. The study also found a correlation between high LGALS3BP expression levels and aggressive histological features of OSCC. Additionally, OSCC cell lines with high LGALS3BP expression showed high sensitivity to the ADC-payload DM4.

ORAL DISEASES (2023)

Add to Collection

Review Oncology

A Contemporary Review of Molecular Therapeutic Targets for Adenoid Cystic Carcinoma

Lauren E. Miller et al.

Summary: This review discusses the advances in molecular targets for adenoid cystic carcinoma (ACC), with MYB-NFIB translocation being the most researched pathway, and other molecular targets showing limited efficacy. The ongoing investigation of molecular abnormalities underlying ACC is critical for identifying and developing novel targeted therapies.

CANCERS (2022)

Add to Collection

Review Chemistry, Multidisciplinary

Non-internalising antibody-drug conjugates

Nicola Ashman et al.

Summary: Traditional antibody-drug conjugates (ADCs) require internalisation into cancer cells, but this approach has limitations. Recent research has shown that extracellular release of drugs upon binding to poorly-internalising antigens or other tumoral components can overcome these limitations. This new approach has the potential to expand the range of cancer targets and improve treatment efficacy.

CHEMICAL SOCIETY REVIEWS (2022)

Add to Collection

Review Biochemistry & Molecular Biology

Adenoid cystic carcinoma: a review of clinical features, treatment targets and advances in improving the immune response to monoclonal antibody therapy

James Nightingale et al.

Summary: The natural history of adenoid cystic carcinoma (ACC) is characterized by treatment failure due to locoregional recurrence and distant metastases. Recent research indicates that ACC is resistant to immune checkpoint inhibition. Targeting PSMA and receptor manipulation may be potential directions for future therapeutic approaches in ACC.

BIOCHIMICA ET BIOPHYSICA ACTA-REVIEWS ON CANCER (2021)

Add to Collection

Review Medicine, Research & Experimental

Role of galectin 3 binding protein in cancer progression: a potential novel therapeutic target

Emily Capone et al.

Summary: LGALS3BP, a secreted protein expressed in most human cells, has been identified as a potential therapeutic target for cancer treatment. Studies have shown that LGALS3BP plays a significant role in cancer, potentially impacting prognosis and functionality.

JOURNAL OF TRANSLATIONAL MEDICINE (2021)

Add to Collection

Review Oncology

Therapeutic Potential of Antibody-Drug Conjugate-Based Therapy in Head and Neck Cancer: A Systematic Review

Vittoria Perrotti et al.

Summary: Despite advancements in understanding molecular mechanisms and developing new therapies for head and neck cancer, the disease remains challenging, with a relatively low 5-year survival rate and limited representation in clinical trials. Targeted therapies tailored for the HNC phenotype may offer new treatment perspectives.

CANCERS (2021)

Add to Collection

Article Oncology

ATR is a MYB regulated gene and potential therapeutic target in adenoid cystic carcinoma

Mattias K. Andersson et al.

ONCOGENESIS (2020)

Add to Collection

Review Oncology

Advanced Adrenocortical Carcinoma (ACC): a Review with Focus on Second-Line Therapies

Luke Ardolino et al.

HORMONES & CANCER (2020)

Add to Collection

Article Oncology

Targeting Vesicular LGALS3BP by an Antibody-Drug Conjugate as Novel Therapeutic Strategy for Neuroblastoma

Emily Capone et al.

CANCERS (2020)

Add to Collection

Article Chemistry, Multidisciplinary

Secreted Gal-3BP is a novel promising target for non-internalizing Antibody-Drug Conjugates

Francesco Giansanti et al.

JOURNAL OF CONTROLLED RELEASE (2019)

Add to Collection

Article Oncology

Alterations of Notch pathway in patients with adenoid cystic carcinoma of the trachea and its impact on survival

Mian Xie et al.

LUNG CANCER (2018)

Add to Collection

Editorial Material Oncology

Taking it up a NOTCH: a novel subgroup of ACC is identified

Renata Ferrarotto et al.

ONCOTARGET (2017)

Add to Collection

Review Otorhinolaryngology

Adenoid cystic carcinoma: A review of recent advances, molecular targets, and clinical trials

Patrick M. Dillon et al.

HEAD AND NECK-JOURNAL FOR THE SCIENCES AND SPECIALTIES OF THE HEAD AND NECK (2016)

Add to Collection

Article Medicine, Research & Experimental

Development and characterization of xenograft model systems for adenoid cystic carcinoma

Christopher A. Moskaluk et al.

LABORATORY INVESTIGATION (2011)

Add to Collection

Article Multidisciplinary Sciences

Recurrent fusion of MYB and NFIB transcription factor genes in carcinomas of the breast and head and neck

Marta Persson et al.

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2009)

Add to Collection

Article Dentistry, Oral Surgery & Medicine

Adenoid cystic carcinoma of the head and neck - a 20 years experience

H Kokemueller et al.

INTERNATIONAL JOURNAL OF ORAL AND MAXILLOFACIAL SURGERY (2004)

Add to Collection

© Peeref 2019-2024. All rights reserved.